Skip to main content

Table 3 Clinicopathological characteristics of HER2 amplified and HER2 non-amplified cases

From: Clinical and molecular characterization of HER2amplified-pancreatic cancer

Clinicopathological characteristics Total cohort, n = 469 HER2 amplification P-value
   Amplified, n = 10 Non-amplified, n = 459  
Sex, n (%)     
 Male 241 (51) 6 (60) 220 (51) 0.7520b
 Female  228 (49) 4 (30) 210 (49)
Age, years     
 Mean 66 64 66 0.5467c
 Median 68 69.5 67.5
 Range 28 to 88 47 to 73 28 to 87
AJCC stage, n (%)     
 1a 17 (3.6) 1 (10) 16 (3.5) 0.4495d
 1b 25 (5.3) 1 (10) 24 (5.2)
 2a 132 (28.1) 3 (30) 129 (28)
 2b 279 (59.5) 4 (40) 275 (60)
 4 16 (3.4) 1 (10) 15 (3)
T stage, n     
 T1 32 1 31  
 T2 64 2 62  
 T3 372 7 365  
 T4 1 0 1  
N stage, n     
 N0 180 6 174  
 N1 289 4 185  
AJCC grade, n     
 1 (well differentiated) 36 0 36 0.1259d
 2 (moderately differentiated) 305 10 295
 3 (poorly differentiated) 125 0 125
 4 (undifferentiated) 3 0 3
Tumour size, mm     
 <=20 105 3 102 0.4695b
 >20 364 7 357
Vascular invasion, n     
 Present 222 2 220 0.1106b
 Absent 247 8 239
Perineural invasion, n     
 Present 339 8 331 0.7336b
 Absent 130 2 128
Tumour location, n     
 Head 381 9 372 0.6961b
 Others 88 1 87
 Margins     
 Clear 301 7 294 1.0000b
 Involved 168 3 165
Outcome     
 Follow-up, months  0.03 to 240 5.0 to 43.6 0.03 to 240 1.0000b
 Median follow-up, months  16 23 16
 Death: PDAC 369 8 361
 Death: other 32 2 30
 Death: unknown 16 0 16
 Alive 49 0 49
 Lost to follow-up 3 0 3
Cancer-specific survival, mean ± SD     
 Length, months 20 ± 19.43 28 ± 19.65 20 ± 19.55 0. 2502c
Recurrence     
 Present 261 8 253  
 Absent 78 1 77  
 Unknown 130 1 129  
Pattern of recurrence, n (% of total n)     
 Lung without liver metastasis 22 (8.4% of 261) 4 (50% of 8) 18 (7.1% of 253) 0.0022b
 Any recurrence without liver metastasis 127 (49% of 261) 8 (100% of 8) 119 (47% of 253) 0.0028b
Adjuvant therapy, n     
 Yes 175 3 172  
 No 289 7 282  
 Unknown 5 0 5  
  1. AJCC, American Joint Committee on Cancer; PDAC, pancreatic ductal adenocarcinoma.
  2. aAJCC Cancer Staging Manual, seventh edition.
  3. bFisher’s exact test.
  4. cUnpaired t-test.
  5. dχ2 test.